MétaCan
Menu
Back to cohort
Record W2623197015 · doi:10.1002/hon.2440

ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING

2017· article· en· W2623197015 on OpenAlexaff
Annalisa Chiappella, Thomas E. Witzig, Umberto Vitolo, Randy D. Gascoyne, Jacqueline Russo, Barbara Amoroso, Krista Hudak, A. Ogunkanmi, Yinyan Xu, Wanda Ruiz, Shailesh Singh, Grzegorz S. Nowakowski

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsLenalidomideDiffuse large B-cell lymphomaMedicineCHOPInternal medicineRituximabOncologyClinical endpointLymphomaRandomized controlled trialMultiple myeloma

Abstract

fetched live from OpenAlex

Introduction: The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is associated with inferior survival following chemoimmunotherapy. Lenalidomide, an immunomodulatory agent, has significant single-agent activity in relapsed/refractory DLBCL, predominantly ABC type, alone and in first line DLBCL plus R-CHOP (i.e., R2-CHOP). Until recently, real-time identification of cell of origin (COO) subtype as a biomarker to inform treatment decisions was not feasible due to technological limitations. The DLC-002 (ROBUST) randomized, phase III study (NCT02285062) is currently evaluating first line R2-CHOP vs placebo–R-CHOP in ABC-DLBCL, as determined by gene expression profiling (GEP). Methods: Patients are randomized 1:1 to oral lenalidomide (15 mg, d1-14/21) + standard R-CHOP or placebo–R-CHOP for 6 cycles with 2 optional, additional rituximab doses. Adult patients must have untreated, ABC-type CD20+ DLBCL, IPI score ≥ 2, and stage II–IV disease. The primary endpoint is progression-free survival (PFS). A central pathology lab determines COO type on FFPE biopsy samples within approximately 3 days using real-time GEP with the NanoString nCounter Dx analysis system. Subtype turnaround time is defined as number of days between central pathology sample receipt and when results are provided to the study site. Results: As of 24 Feb 2017, DLBCL subtyping was attempted in 1,530 patients, of whom 1,402 had samples successfully tested. COO results were 43% ABC and 57% non-ABC (GCB + unclassified). Samples from 128 patients, or about 8% of those screened for COO, were unacceptable due to various technical reasons such as incorrect or insufficient material, and low tissue RNA concentration or purity. Samples were analyzed in four central pathology labs located in the UK (X2), USA, and China, which together achieved a mean turnaround time of 2.56 days. As of 24 Feb 2017, 439 patients were randomized to treatment in ROBUST. Conclusions: Enrollment began in Jan 2015, with the goal of randomizing 560 patients by Aug 2017. Real-time COO assessment is feasible in this study with a short turnaround time. The percentage of ABC patients is similar to that reported in the literature. The ROBUST study is the first phase III trial of ABC-type DLBCL to use real-time GEP for patient eligibility, thus providing a significant advance in precision therapy in DLBCL. Keywords: activated B-cell-like (ABC); diffuse large B-cell lymphoma (DLBCL); lenalidomide.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.587
Threshold uncertainty score0.930

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0040.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.081
GPT teacher head0.373
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207